

Amendments to the Specification:

At page 1, add a paragraph above "BACKGROUND" to read as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of co-pending Application No. 10/374,539, filed February 25, 2003, which claims the priority under 35 USC 120 to Application No. 06/361,475, filed March 1, 2002, all of which are incorporated herein by reference.

Please replace paragraph [0013] with the following paragraph:

[0013] The terms "type 2 diabetes," "type II diabetes," "type 2 diabetes mellitus," "type II diabetes mellitus," "non-insulin-dependent diabetes," and "non-insulin-dependent diabetes mellitus (NIDDM)" are used interchangeably, and refer to a chronic diseases characterized by insulin resistance at the level of fat and muscle cells and resultant hyperglycemia.

Please replace paragraph [0072] with the following paragraph:

[0072] The term "alkynyl" or "unsubstituted alkynyl" refers to a hydrocarbon with at least one carbon-carbon triple bond.

Please replace paragraph [0073] with the following paragraph:

[0073] The term "aryl" or "unsubstituted aryl" refers to a mono or polycyclic unsaturated moieties having at least one aromatic ring. The term includes heteroaryls that include one or more heteroatoms within the at least one aromatic ring. Illustrative examples of aryl include: phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.

Please replace paragraph [0086] with the following paragraph:

[0086] In another aspect of the present invention, a method for treating ~~diabetes~~ obesity is provided comprising administering to a subject in need thereof a therapeutically effective amount of a PTP-1B exosite inhibitor.